Predictive value of classical risk factors and their control in coronary patients: A follow-up of the EUROASPIRE I cohort

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 10, Issue 4, 2003, Pages 289-295

  De Bacquer, Dirk ^a   De Backer, Guy ^a   Östör, Erika ^b   Simon, Jaroslav ^c   Pyörälä, Kalevi ^d  

^a GHENT UNIVERSITY   (Belgium)

^b Hungarian Institute of Cardiology   (Hungary)

^c CHARLES UNIVERSITY   (Czech Republic)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Coronary heart disease; Mortality; Secondary prevention

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID;

ACUTE HEART INFARCTION; ADULT; AGED; ANALYTIC METHOD; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DATA ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; EDUCATION; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; RISK FACTOR; SAMPLE; SMOKING; STANDARD; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0242468753     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/00149831-200308000-00012     Document Type: Article

References (17)

1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19:1434-1503.
2. The EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18:1569-1582.
3. The EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22:554-572.
4. International classification of diseases: manual of the international statistical classification of diseases, injuries, and causes of death: based on recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-ninth World Health Assembly. Geneva: World Health Organization; 1977.
5. World Health Organization. International statistical classification of diseases and related health problem, Tenth Revision. Geneva: World Health Organization; 1992.
6. Parmar M, Machin D. Survival analysis: a practical approach. Chichester, West Sussex (UK): Wiley & Sons; 1995.
7. The SAS system. Release 6.12, Cary, North Carolina: SAS Institute Inc.
8. The EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357:995-1001.
9. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
12. Heart Protection Study Collaborative Group. MRF/BHF Heart Protection Study of cholesterol lowering in 20,536 individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
13. Wilhelmsen L, Pyörälä K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001; 22: 1119-1127.
14. Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from The Long-term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001; 38:56-63.
15. Marchioli R, Avanzini F, Barzi F, et al. on behalf of GISSI-Prevenzione Investigators. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22:2085-2103.
16. Pfeffer MA, Sacks FM, Moye LA, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial - why we need a trial now. J Am Coll Cardiol 1999; 33:125-130.
17. Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100:475-482.